Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas. In a single-cen...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00767/full |
| _version_ | 1819092583924629504 |
|---|---|
| author | Yaqing Cao Wenyi Lu Rui Sun Xin Jin Lin Cheng Xiaoyuan He Luqiao Wang Ting Yuan Cuicui Lyu Mingfeng Zhao |
| author_facet | Yaqing Cao Wenyi Lu Rui Sun Xin Jin Lin Cheng Xiaoyuan He Luqiao Wang Ting Yuan Cuicui Lyu Mingfeng Zhao |
| author_sort | Yaqing Cao |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas. In a single-center study, we evaluated the safety and efficacy of a combination therapy with CD19 CAR-T cells and an anti-PD-1 antibody (nivolumab) in patients with relapsed/refractory B-NHL. A total of 11 patients with refractory/relapsed B-NHL were recruited and subsequently received CD19 CAR-T cells and nivolumab. The primary end points were safety and feasibility. The infusions were safe, and no dose-limiting toxicities occurred. Grade 1 or 2 cytokine release syndrome (CRS) was observed in 25% (3/11) and 50% (6/11) of the patients, respectively, and only one patient (1/11) experienced neurotoxicity. The objective response rate (ORR) and complete response (CR) rate were 81.81% (9/11) and 45.45% (5/11), respectively. The median follow-up time was 6 (1~15) months. The median progression-free survival (PFS) time was 6 months (1~14 months), and 3 patients continued to have a response at the time of this writing. Our study demonstrated that the combination of CD19 CAR-T cells and nivolumab was feasible and safe and mediated potent anti-lymphoma activity, which should be examined further in prospective clinical trials in refractory/relapsed B-NHL. |
| first_indexed | 2024-12-21T22:57:56Z |
| format | Article |
| id | doaj.art-49143d5989184f25b8bb4e43191e72c8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T22:57:56Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-49143d5989184f25b8bb4e43191e72c82022-12-21T18:47:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-08-01910.3389/fonc.2019.00767467023Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin LymphomaYaqing Cao0Wenyi Lu1Rui Sun2Xin Jin3Lin Cheng4Xiaoyuan He5Luqiao Wang6Ting Yuan7Cuicui Lyu8Mingfeng Zhao9The First Central Clinical College of Tianjin Medical University, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaThe First Central Clinical College of Tianjin Medical University, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaThe First Central Clinical College of Tianjin Medical University, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaThe First Central Clinical College of Tianjin Medical University, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaChimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas. In a single-center study, we evaluated the safety and efficacy of a combination therapy with CD19 CAR-T cells and an anti-PD-1 antibody (nivolumab) in patients with relapsed/refractory B-NHL. A total of 11 patients with refractory/relapsed B-NHL were recruited and subsequently received CD19 CAR-T cells and nivolumab. The primary end points were safety and feasibility. The infusions were safe, and no dose-limiting toxicities occurred. Grade 1 or 2 cytokine release syndrome (CRS) was observed in 25% (3/11) and 50% (6/11) of the patients, respectively, and only one patient (1/11) experienced neurotoxicity. The objective response rate (ORR) and complete response (CR) rate were 81.81% (9/11) and 45.45% (5/11), respectively. The median follow-up time was 6 (1~15) months. The median progression-free survival (PFS) time was 6 months (1~14 months), and 3 patients continued to have a response at the time of this writing. Our study demonstrated that the combination of CD19 CAR-T cells and nivolumab was feasible and safe and mediated potent anti-lymphoma activity, which should be examined further in prospective clinical trials in refractory/relapsed B-NHL.https://www.frontiersin.org/article/10.3389/fonc.2019.00767/fullB-cell non-Hodgkin lymphoma (B-NHL)anti-CD19 chimeric antigen receptor T cellsimmune check point blocadecombinationsafe and effective |
| spellingShingle | Yaqing Cao Wenyi Lu Rui Sun Xin Jin Lin Cheng Xiaoyuan He Luqiao Wang Ting Yuan Cuicui Lyu Mingfeng Zhao Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma Frontiers in Oncology B-cell non-Hodgkin lymphoma (B-NHL) anti-CD19 chimeric antigen receptor T cells immune check point blocade combination safe and effective |
| title | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| title_full | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| title_fullStr | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| title_full_unstemmed | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| title_short | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| title_sort | anti cd19 chimeric antigen receptor t cells in combination with nivolumab are safe and effective against relapsed refractory b cell non hodgkin lymphoma |
| topic | B-cell non-Hodgkin lymphoma (B-NHL) anti-CD19 chimeric antigen receptor T cells immune check point blocade combination safe and effective |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00767/full |
| work_keys_str_mv | AT yaqingcao anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT wenyilu anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT ruisun anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT xinjin anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT lincheng anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT xiaoyuanhe anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT luqiaowang anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT tingyuan anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT cuicuilyu anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma AT mingfengzhao anticd19chimericantigenreceptortcellsincombinationwithnivolumabaresafeandeffectiveagainstrelapsedrefractorybcellnonhodgkinlymphoma |